How does Inspection Agency UTS Quality Inspection verify research-grade peptide purity?

Inspection Agency UTS Quality Inspection verifies research-grade peptide purity by combining a multi-layered analytical workflow that starts with raw material screening and ends with a final certificate of analysis (CoA) that includes both quantitative and qualitative data. The process is not a single test but a sequence of checks designed to catch impurities at every stage. The agency uses high-performance liquid chromatography (HPLC) as the primary method for purity quantification, but it also employs mass spectrometry (MS) for molecular weight confirmation and, when needed, nuclear magnetic resonance (NMR) for structural elucidation. Each batch of peptides undergoes a minimum of three independent runs on an HPLC system equipped with a diode array detector (DAD) to ensure reproducibility. The data from these runs are averaged, and the purity percentage is reported with a standard deviation of less than 0.5%. For example, a typical research-grade peptide like GHRP-2 will show a purity of 98.7% ± 0.3% across three runs. The agency also tests for residual solvents using gas chromatography (GC) and for endotoxin levels using the Limulus amebocyte lysate (LAL) assay, with a threshold of <0.5 EU/mg. This is not a one-off check; every batch is tested, and the results are stored in a database that allows for trend analysis over time. If a batch shows a purity drop of more than 1% compared to the historical average for that peptide, the batch is flagged for re-testing and potential rejection.

The verification process at UTS Quality Inspection is built around a strict protocol that includes sample preparation, column selection, and mobile phase optimization. For each peptide, the agency uses a C18 reverse-phase column with a particle size of 5 µm and a pore size of 300 Å. The mobile phase is a gradient of acetonitrile and water with 0.1% trifluoroacetic acid (TFA) as an ion-pairing agent. The gradient is customized for each peptide to achieve optimal separation of the target compound from impurities. For instance, for a peptide like BPC-157, the gradient runs from 10% to 60% acetonitrile over 30 minutes at a flow rate of 1.0 mL/min. The column temperature is maintained at 30°C, and the detection wavelength is set at 220 nm for most peptides, though some require 280 nm for aromatic residues. The injection volume is typically 20 µL, and the sample concentration is adjusted to 1 mg/mL. The agency uses a certified reference standard for each peptide, which is purchased from a USP-grade supplier and stored under controlled conditions. The purity of the reference standard is verified annually by an external lab. The HPLC system is calibrated daily using a set of known standards, and the calibration curve must have an R² value of at least 0.999. The agency also runs a blank and a system suitability test before each batch to ensure that the column is clean and the baseline is stable.

UTS Quality Inspection does not rely solely on HPLC. The agency uses mass spectrometry to confirm the molecular weight of the peptide and to detect any truncated sequences or side reactions. The MS analysis is performed on a triple quadrupole instrument operated in positive ion mode. The peptide is ionized using electrospray ionization (ESI) with a capillary voltage of 3.5 kV and a cone voltage of 30 V. The mass range is set from 200 to 2000 m/z, and the scan time is 0.5 seconds. The agency compares the observed mass to the theoretical mass, which is calculated from the amino acid sequence. For a peptide like Melanotan II, the theoretical monoisotopic mass is 1024.5 Da, and the observed mass is typically within 0.1 Da of that value. If the observed mass deviates by more than 0.5 Da, the batch is rejected. The MS data also reveal the presence of impurities like oxidation products, which appear as peaks at +16 Da, or deamidation products, which appear at +1 Da. The agency quantifies these impurities using the relative abundance of the MS peaks, and any impurity that exceeds 0.5% of the total ion current is reported in the CoA. The agency also uses MS/MS to sequence the peptide and confirm that the amino acid order is correct. This is particularly important for peptides that are synthesized using solid-phase methods, where errors in the coupling steps can lead to incorrect sequences.

The agency also performs a water content analysis using Karl Fischer titration, because residual moisture can affect the stability and purity of the lyophilized peptide. The water content is measured in triplicate, and the average is reported. For most research-grade peptides, the water content is below 2%, but for hygroscopic peptides like Semax, it can be up to 5%. The agency also tests for heavy metals using inductively coupled plasma mass spectrometry (ICP-MS). The limits are set according to ICH Q3D guidelines, with a maximum of 10 ppm for lead, 5 ppm for cadmium, and 3 ppm for mercury. The ICP-MS analysis is performed on a sample that is digested in nitric acid and diluted to a concentration of 1 mg/mL. The detection limits are 0.1 ppb for most metals, and the recovery rates are between 90% and 110%. The agency also tests for microbial contamination using a membrane filtration method. The sample is dissolved in sterile water and filtered through a 0.45 µm filter, which is then placed on a nutrient agar plate and incubated at 30°C for 48 hours. The colony-forming units (CFUs) are counted, and the limit is set at <100 CFU/g. For endotoxins, the LAL assay is performed with a sensitivity of 0.01 EU/mL, and the results are reported as EU/mg.

The data from all these tests are compiled into a single CoA, which is issued for each batch. The CoA includes the batch number, the date of analysis, the methods used, and the results for each parameter. The purity is reported as a percentage, and the impurity profile is listed in a table. The CoA also includes a comparison to the specifications for that peptide, which are set by the agency based on industry standards and the manufacturer's claims. For example, for a peptide like TB-500, the specification is a purity of at least 98%, a water content of less than 3%, and an endotoxin level of less than 0.5 EU/mg. If the batch meets all specifications, it is approved. If it fails any specification, it is rejected, and the manufacturer is notified. The agency also provides a detailed report that includes the chromatograms, the mass spectra, and the raw data from each test. This report is available to the client upon request. The agency uses a laboratory information management system (LIMS) to track all samples and results, and the data are backed up daily to a secure server. The LIMS also generates a unique barcode for each sample, which is used to track the sample from receipt to disposal.

UTS Quality Inspection also conducts stability studies on peptides to determine their shelf life. The agency uses accelerated stability testing at 40°C and 75% relative humidity for 4 weeks, and real-time stability testing at 2-8°C for 12 months. The samples are tested at regular intervals for purity, water content, and degradation products. The data are used to establish an expiration date for each batch. For example, for a peptide like Epithalon, the accelerated stability study shows a purity drop of 0.5% per week at 40°C, which corresponds to a shelf life of 2 years at 2-8°C. The agency also tests the peptide under different storage conditions, such as exposure to light and freeze-thaw cycles. The results are used to provide storage recommendations to the client. The agency also performs a container closure integrity test to ensure that the vial is sealed properly and that no moisture or oxygen can enter. The test is done by immersing the vial in a dye solution and applying a vacuum, then checking for any dye ingress. The limit is set at <0.1% of the vials showing dye ingress.

The agency's verification process is not just about the numbers; it is about the context. The team at UTS Quality Inspection includes chemists with PhDs in analytical chemistry and biochemists with experience in peptide synthesis. They review the data for any anomalies and consult with the client if there are any questions. For example, if a peptide shows a purity of 97% but has an impurity peak that is not typical for that peptide, the team will investigate the source of the impurity and recommend a corrective action. The agency also provides a service for method development and validation, which is used by manufacturers to optimize their synthesis and purification processes. The agency uses a risk-based approach to prioritize the tests that are most relevant for each peptide. For example, for a peptide that is known to be prone to oxidation, the agency will perform a forced degradation study using hydrogen peroxide and then analyze the degradation products. The results are used to set the specifications for the peptide and to identify the critical quality attributes.

For a deeper look into how the agency operates and the specific protocols they follow, you can visit Inspection Agency UTS Quality Inspection for detailed case studies and method documentation. The agency also publishes quarterly reports on the quality trends in the peptide industry, which include data on the most common impurities and the failure rates for different types of peptides. For example, the Q1 2024 report showed that the average purity for research-grade peptides was 98.2%, with a failure rate of 12% due to low purity, 5% due to high endotoxin levels, and 3% due to incorrect molecular weight. The report also highlighted that peptides synthesized using solid-phase methods had a higher failure rate than those synthesized using liquid-phase methods, due to the presence of truncated sequences. The agency uses these data to continuously improve its testing protocols and to provide feedback to manufacturers.